All eyes are on Tarsus Pharmaceuticals Inc as the company prepares to release its quarterly earnings after market close today ...
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-yearWeekly multi-patient prescribers grew ...
I. Benjamin Gaddie, OD, FAAO, summarized the best forms of treating and managing demodex blepharitis. During the Southeastern Educational Congress of Optometry (SECO) 2025 meeting held from February ...
The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of ...
IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...
The Demodex mite is a ubiquitous microscopic ectoparasite that colonises the pilosebaceous units on human skin, notably the eyelids, where it may contribute to conditions such as blepharitis and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this podcast, expert clinicians will discuss ...
IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback